Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
46 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Blepharitis - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Blepharitis - Pipeline Review, H1 2015', provides an overview of the Blepharitis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Blepharitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Blepharitis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Blepharitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Blepharitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Blepharitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Blepharitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Blepharitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Blepharitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Blepharitis Overview 6 Therapeutics Development 7 Pipeline Products for Blepharitis - Overview 7 Pipeline Products for Blepharitis - Comparative Analysis 8 Blepharitis - Therapeutics under Development by Companies 9 Blepharitis - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Unknown Stage Products 13 Blepharitis - Products under Development by Companies 14 Blepharitis - Companies Involved in Therapeutics Development 15 Foamix Pharmaceuticals Ltd. 15 InSite Vision Incorporated 16 Laboratoires Thea S.A. 17 Novaliq GmbH 18 Blepharitis - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Combination Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 28 (azithromycin + dexamethasone) - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 azithromycin - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 dexamethasone - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 ISV-405 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 minocycline Gel - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Nov-137 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Blepharitis - Recent Pipeline Updates 35 Blepharitis - Dormant Projects 37 Blepharitis - Product Development Milestones 38 Featured News & Press Releases 38 Jul 08, 2014: InSite Vision Plans to Submit New Drug Application to FDA for DexaSite� for the Treatment of Blepharitis in Adults 38 Jul 23, 2013: InSite Vision Announces Top-line Results from the DOUBle Phase 3 Clinical Study for the Treatment of Moderate-to-Severe Blepharitis 39 Mar 25, 2013: InSite Vision Completes DOUBle Phase III Clinical Study Of AzaSite Plus And DexaSite For Treatment Of Blepharitis 39 Sep 07, 2012: InSite Vision Fully Enrolls Phase III DOUBle Clinical Study Of AzaSite Plus And DexaSite For Blepharitis 41 May 25, 2011: InSite Vision Receives SPA From FDA For DOUBle Phase III Clinical Trial Of AzaSite Plus And DexaSite 42 Apr 14, 2011: InSite Vision Updates Special Protocol Assessment Submission To FDA For Phase III Trial Of AzaSite Plus And DexaSite 43 Apr 26, 2010: Foamix is granted a fourth U.S. patent for OilGel, directed to pharmaceutical compositions and their dermatological, gynecological and ophthalmic applications 44 Appendix 45 Methodology 45 Coverage 45 Secondary Research 45 Primary Research 45 Expert Panel Validation 45 Contact Us 46 Disclaimer 46
List of Tables Number of Products under Development for Blepharitis, H1 2015 7 Number of Products under Development for Blepharitis - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Comparative Analysis by Late Stage Development, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 11 Comparative Analysis by Early Stage Development, H1 2015 12 Comparative Analysis by Unknown Stage Development, H1 2015 13 Products under Development by Companies, H1 2015 14 Blepharitis - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 15 Blepharitis - Pipeline by InSite Vision Incorporated, H1 2015 16 Blepharitis - Pipeline by Laboratoires Thea S.A., H1 2015 17 Blepharitis - Pipeline by Novaliq GmbH, H1 2015 18 Assessment by Monotherapy Products, H1 2015 19 Assessment by Combination Products, H1 2015 20 Number of Products by Stage and Target, H1 2015 22 Number of Products by Stage and Mechanism of Action, H1 2015 24 Number of Products by Stage and Route of Administration, H1 2015 26 Number of Products by Stage and Molecule Type, H1 2015 27 Blepharitis Therapeutics - Recent Pipeline Updates, H1 2015 35 Blepharitis - Dormant Projects, H1 2015 37
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
